[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432678":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":58,"collaborators":41,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":41,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":41,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":45,"whyStopped":41,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Damanhour Teaching Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (n=30)","ACTIVE_COMPARATOR","Atenolol group",[13],"Drug: Atenolol Succinate Oral Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"Group M (n=30)","Metoprolol group",[18],"Drug: Metoprolol Succinate Oral Tablet",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Atenolol Succinate Oral Tablet","Atenolol 50 mg",[9],[26],"Tenormin tablets",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Metoprolol Succinate Oral Tablet","Metoprolol 100 mg",[15],[32],"Seloken ZOC tablets",[34],{"name":35,"affiliation":5,"role":36},"Ahmed M Shaat, MD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","00201223482709",null,"ahmedshaat99@gmail.com",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":41,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Damanhūr","El-Beheira","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],30.95,27.38333,{"lat":54,"lon":53},[57],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},{"type":59,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100432678","phase-4-premedication-with-atenolol-versus-metoprolol-for-controlled-hypotensive-anesthesia-during-nasal-surgeries-100432678",false,"NCT04914234","Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries","Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status ≤ II\n* Age from 21 to 50 years\n\nExclusion Criteria:\n\n* ASA physical status \\> II\n* Age \\\u003C 21 years or \\> 50 years\n* Pregnant women\n* Breastfeeding\n* Bronchial asthma\n* Chronic obstructive pulmonary disease\n* Diabetes Mellitus\n* Hypertension\n* Ischemic heart disease\n* Rheumatic heart disease\n* Heart failure\n* Heart block\n* Sick sinus syndrome\n* Sinus bradycardia\n* Chronic hypotension\n* Anemia (Hb \\\u003C 10 g\u002Fdl)\n* Renal or hepatic dysfunction\n* Central nervous system disease\n* Allergic fungal sinusitis\n* Patients on beta-blockers\n* Alcohol or drug abuse\n* Anticoagulation therapy,\n* Bleeding diathesis\n* Agents influencing autonomic nervous system\n* Allergy to the study drugs\n* Any contraindication of oral intake","ALL","21 Years","50 Years",{"count":71,"type":72},60,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","Objectives: To compare the safety and efficacy of oral atenolol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during nasal surgeries.\n\nBackground: Mucosal bleeding is the most frequent complication with nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, increases operation time, and consequently increases blood loss. There are several pharmacological and non-pharmacological techniques for the appropriate control of intraoperative bleeding.\n\nPatients and Methods: This was a prospective, randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received oral atenolol, and group M, received oral metoprolol.",[78],"Hypotension Drug-Induced",[80,81,82,83],"atenolol","controlled hypotension","metoprolol","nasal surgery","2025-08-20",{"date":86,"type":87},"2025-08-21","ACTUAL",{"date":89,"type":87},"2025-08-01",{"date":91,"type":72},"2026-01-30",{"name":5,"class":6},1]